237 related articles for article (PubMed ID: 24419643)
21. Therapeutic plasma exchange and immunosuppressive therapy in a patient with anti-GAD antibody-related epilepsy: quantification of the antibody response.
Farooqi MS; Lai Y; Lancaster E; Schmitt SE; Sachais BS
J Clin Apher; 2015 Feb; 30(1):8-14. PubMed ID: 24961613
[TBL] [Abstract][Full Text] [Related]
22. Acute Cerebellar Ataxia Associated with Anti-glutamic Acid Decarboxylase Antibodies Mimicking Miller Fisher Syndrome.
Nakamura Y; Nakajima H; Hosokawa T; Yamane K; Ishida S; Kimura F
Intern Med; 2018 Jan; 57(2):269-271. PubMed ID: 29093402
[TBL] [Abstract][Full Text] [Related]
23. Lesson of the month 2: Autoimmune sequelae of anti-GAD antibodies - thinking outside the box.
Ward RJ; Varughese GI; Jose B; Abraham RJ
Clin Med (Lond); 2017 Oct; 17(5):473-474. PubMed ID: 28974603
[TBL] [Abstract][Full Text] [Related]
24. Presynaptic inhibition of cerebellar GABAergic transmission by glutamate decarboxylase autoantibodies in progressive cerebellar ataxia.
Takenoshita H; Shizuka-Ikeda M; Mitoma H; Song S; Harigaya Y; Igeta Y; Yaguchi M; Ishida K; Shoji M; Tanaka M; Mizusawa H; Okamoto K
J Neurol Neurosurg Psychiatry; 2001 Mar; 70(3):386-9. PubMed ID: 11181864
[TBL] [Abstract][Full Text] [Related]
25. A case report of anti-GAD65 antibody-positive autoimmune encephalitis in children associated with autoimmune polyendocrine syndrome type-II and literature review.
Sapana T; Li W; Tian F; Yan W; Dou B; Hua S; Zhuo Z
Front Immunol; 2023; 14():1274672. PubMed ID: 38077387
[TBL] [Abstract][Full Text] [Related]
26. The neurological syndromes associated with glutamic acid decarboxylase antibodies.
Baizabal-Carvallo JF
J Autoimmun; 2019 Jul; 101():35-47. PubMed ID: 31000408
[TBL] [Abstract][Full Text] [Related]
27. Low-Titre GAD Antibody-Associated Late-Onset Cerebellar Ataxia with a Significant Clinical Response to Intravenous Immunoglobulin Treatment.
Petrijan T; Menih M
Cerebellum; 2017 Aug; 16(4):868-871. PubMed ID: 28321713
[TBL] [Abstract][Full Text] [Related]
28. Selective suppression of cerebellar GABAergic transmission by an autoantibody to glutamic acid decarboxylase.
Ishida K; Mitoma H; Song SY; Uchihara T; Inaba A; Eguchi S; Kobayashi T; Mizusawa H
Ann Neurol; 1999 Aug; 46(2):263-7. PubMed ID: 10443895
[TBL] [Abstract][Full Text] [Related]
29. [Anti-GAD antibodies in paraneoplastic cerebellar ataxia associated with limbic encephalitis and autonomic dysfunction].
Carra-Dalliere C; Thouvenot E; Bonafé A; Ducray F; Touchon J; Charif M
Rev Neurol (Paris); 2012 Apr; 168(4):363-6. PubMed ID: 22405456
[TBL] [Abstract][Full Text] [Related]
30. Cerebellar ataxia associated with anti-glutamic acid decarboxylase autoantibodies.
Vianello M; Tavolato B; Armani M; Giometto B
Cerebellum; 2003; 2(1):77-9. PubMed ID: 12882238
[TBL] [Abstract][Full Text] [Related]
31. A Case of Treatment Resistance and Complications in a Patient with Stiff Person Syndrome and Cerebellar Ataxia.
Jones LA; Baber W; Wardle M; Robertson NP; Morris HR; Church A; Llewelyn JG; Peall KJ
Tremor Other Hyperkinet Mov (N Y); 2019; 9():. PubMed ID: 31646058
[TBL] [Abstract][Full Text] [Related]
32. Anti-GAD Antibodies and the Cerebellum: Where Do We Stand?
Manto M; Mitoma H; Hampe CS
Cerebellum; 2019 Apr; 18(2):153-156. PubMed ID: 30343467
[TBL] [Abstract][Full Text] [Related]
33. GABA-A receptor impairment in cerebellar ataxia with anti-glutamic acid decarboxylase antibodies.
Hosoi Y; Suzuki-Sakao M; Terada T; Konishi T; Ouchi Y; Miyajima H; Kono S
J Neurol; 2013 Dec; 260(12):3086-92. PubMed ID: 24091766
[TBL] [Abstract][Full Text] [Related]
34. The role of IVIg in the treatment of patients with stiff person syndrome and other neurological diseases associated with anti-GAD antibodies.
Dalakas MC
J Neurol; 2005 May; 252 Suppl 1():I19-25. PubMed ID: 15959668
[TBL] [Abstract][Full Text] [Related]
35. Vertical nystagmus associated with glutamic acid decarboxylase antibodies responding to cyclophosphamide.
Baizabal-Carvallo JF; Alonso-Juarez M
J Neuroimmunol; 2018 Apr; 317():5-7. PubMed ID: 29501085
[TBL] [Abstract][Full Text] [Related]
36. T-cell reactivity to glutamic acid decarboxylase in stiff-man syndrome and cerebellar ataxia associated with polyendocrine autoimmunity.
Costa M; Saiz A; Casamitjana R; Castañer MF; Sanmartí A; Graus F; Jaraquemada D
Clin Exp Immunol; 2002 Sep; 129(3):471-8. PubMed ID: 12197888
[TBL] [Abstract][Full Text] [Related]
37. High Titer of Circulating Antiglutamic Acid Decarboxylase Antibodies in a Patient with Cerebellar Ataxia and Type 1 Diabetes.
Kataria R; Fernandes S; Lebastchi J; Bravo CA; Sena KN
Conn Med; 2017 Mar; 81(3):161-164. PubMed ID: 29772159
[TBL] [Abstract][Full Text] [Related]
38. A patient with type 1 diabetes mellitus and cerebellar ataxia associated with high titer of circulating anti-glutamic acid decarboxylase antibodies.
Iwasaki H; Sato R; Shichiri M; Hirata Y
Endocr J; 2001 Apr; 48(2):261-8. PubMed ID: 11456277
[TBL] [Abstract][Full Text] [Related]
39. [Steroid treatment in four cases of anti-GAD cerebellar ataxia].
Bonnan M; Cabre P; Olindo S; Signate A; Saint-Vil M; Smadja D
Rev Neurol (Paris); 2008 May; 164(5):427-33. PubMed ID: 18555874
[TBL] [Abstract][Full Text] [Related]
40. Anti-GAD antibodies and periodic alternating nystagmus.
Tilikete C; Vighetto A; Trouillas P; Honnorat J
Arch Neurol; 2005 Aug; 62(8):1300-3. PubMed ID: 16087772
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
